Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07805135 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer

Name: A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer — clinical trial record (NCT07805135)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorCSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Started2026-08-31

View on ClinicalTrials.gov ↗

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

42 trials monitored

See 1 trial at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This is a randomized, open-label, multicenter Phase Ⅲ clinical trial designed to evaluate the efficacy and safety of HB1801 versus Taxotere® in patients with HER2-negative advanced breast cancer.

Trial Details

NCT Number	NCT07805135
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	HER2-Negative Advanced Breast Cancer
Enrollment	430 participants
Start Date	2026-08-31
Primary Completion	2028-06-01 (estimated)
Study Completion	2029-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-04